Galectin Therapeutics Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing galectin-targeting therapies for fibrotic disease and cancer. Its lead candidate is belapectin, focused primarily on NASH cirrhosis and prevention of esophageal varices, with an additional investigational oncology program.
This quarterly report covers the three months ended March 31, 2023. The financial statements are unaudited. The company had 59.6 million common shares outstanding as of May 8, 2023.
Financial condition and key metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue in either period |
| Research and development expense | $8.8 million | $8.1 million | Up 9% |
| General and administrative expense | $1.5 million | $1.9 million | Down 18% |
| Total operating loss | $10.3 million | $9.9 million | Higher loss |
| Net loss | $11.5 million | $9.9 million | Higher loss |
| Net loss per common share | $0.19 | $0.17 | Higher loss per share |
| Net cash used in operating activities | $10.8 million | $8.0 million | Use increased by $2.8 million |
R&D spending was driven primarily by clinical activities, including the NAVIGATE trial. Clinical activity expense was $6.8 million, compared with $6.9 million in the prior-year quarter; preclinical and other R&D expenses increased.
Cash and cash equivalents were $17.8 million at March 31, 2023, compared with $18.6 million at December 31, 2022. The cash flow statement reports ending cash of $18.0 million, which does not reconcile to the balance sheet value; the filing text does not provide a clear explanation for this difference.
Total liabilities were $62.9 million at March 31, 2023, including approximately $30.2 million of related-party convertible notes, $19.7 million outstanding under a related-party convertible line of credit, $11.5 million of current liabilities, and $1.3 million of derivative liabilities. Stockholders’ deficit was $44.4 million.
The company drew an additional $10.0 million under its chairman’s $60.0 million unsecured convertible line of credit on March 31, 2023, leaving $40.0 million available. The draw bears interest at 6.41%, is due by January 31, 2026, and is convertible at the lender’s option at $3.00 per share. The company issued 200,000 warrants in connection with the draw.
Material changes versus the prior comparable period
- Net loss increased by $1.6 million, primarily because of higher R&D costs and a $769,000 unfavorable change in the fair value of derivative liabilities, compared with favorable derivative fair-value changes in Q1 2022.
- R&D expense increased $741,000, largely from additional employees and other R&D activities.
- G&A expense decreased $334,000, primarily because of lower insurance expense and approximately $241,000 less stock-based compensation.
- Operating cash burn increased from $8.0 million to $10.8 million.
- The company’s related-party line-of-credit borrowings increased by $10.0 million during the quarter, while cash declined only $793,000 after financing proceeds.
- Common shares outstanding increased to 59.6 million from 59.4 million at year-end 2022. Potentially dilutive instruments were substantial, including 11.8 million warrants, 6.5 million options, and shares issuable upon conversion of related-party debt and preferred stock.
Guidance, outlook, risks and unusual items
The company completed randomization of 357 patients in the NAVIGATE Phase 2b/3 trial in February 2023 and expects topline interim-analysis results in fall 2024. More than 150 sites in 14 countries had been activated. The planned interim analysis may support dose selection, sample-size or randomization changes, or termination for efficacy or futility.
Management believes available cash and the remaining availability under the related-party credit line are sufficient to fund currently planned operations through at least December 31, 2024. The company expects to require additional financing thereafter and may pursue debt, equity, collaboration, partnership, or other strategic transactions. There is no assurance that financing will be available on acceptable terms.
The proposed Phase 2 oncology trial of belapectin with a checkpoint inhibitor for recurrent or metastatic head and neck cancer is dependent on financing and therefore has no stated commencement date.
- The company has incurred losses since inception, has generated no revenue, and expects losses to continue.
- Clinical trials may be delayed, fail to demonstrate safety or efficacy, or be suspended by regulators.
- Regulatory approval and commercialization remain uncertain, and the company depends on additional capital and potential strategic partners.
- COVID-19-related disruptions, particularly in Europe, previously affected site activation and enrollment; the company expanded into Latin America.
- Related-party financing creates concentration risk and potential dilution. The outstanding notes mature in 2025, while the line-of-credit obligations are due in 2026 unless converted.
- Derivative liabilities are Level 3 estimates and produced a $769,000 expense in the quarter due to fair-value changes.
- The company reported no significant pending legal proceedings, no defaults, and no unregistered equity sales during the quarter.
Important facts for investors to verify
- Reconcile the $17.8 million balance-sheet cash figure with the $18.0 million ending cash amount reported in the cash flow statement.
- Review NAVIGATE interim-analysis timing, enrollment status, trial execution, and the expected fall 2024 topline readout.
- Assess whether the $40.0 million remaining related-party credit availability will be sufficient through the stated funding horizon and review its conversion and warrant terms.
- Monitor the company’s operating cash burn, accrued clinical-trial obligations, and need for financing after December 31, 2024.
- Evaluate dilution from 11.8 million outstanding warrants, 6.5 million options, convertible debt, the credit line, and preferred stock.
- Review the assumptions and sensitivity of the Level 3 derivative liabilities and the resulting non-cash earnings volatility.
- Confirm the timing and financing requirements for the proposed oncology trial.